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Abstract
Background: Psalmopeotoxin I (PcFK1), a protein of 33 aminoacids derived from the venom of the spider Psalmopoeus
Cambridgei, is able to inhibit the growth of Plasmodium falciparum malaria parasites with an IC50 in the low micromolar
range. PcFK1 was proposed to act as an ion channel inhibitor, although experimental validation of this mechanism is
lacking. The surface loops of PcFK1 have some sequence similarity with the parasite protein sequences cleaved by PfSUB1, a
subtilisin-like protease essential for egress of Plasmodium falciparum merozoites and invasion into erythrocytes. As PfSUB1
has emerged as an interesting drug target, we explored the hypothesis that PcFK1 targeted PfSUB1 enzymatic activity.
Findings: Molecular modeling and docking calculations showed that one loop could interact with the binding site of
PfSUB1. The calculated free energy of binding averaged 25.01 kcal/mol, corresponding to a predicted low-medium
micromolar constant of inhibition. PcFK1 inhibited the enzymatic activity of the recombinant PfSUB1 enzyme and the in
vitro P.falciparum culture in a range compatible with our bioinformatics analysis. Using contact analysis and free energy
decomposition we propose that residues A14 and Q15 are important in the interaction with PfSUB1.
Conclusions: Our computational reverse engineering supported the hypothesis that PcFK1 targeted PfSUB1, and this was
confirmed by experimental evidence showing that PcFK1 inhibits PfSUB1 enzymatic activity. This outlines the usefulness of
advanced bioinformatics tools to predict the function of a protein structure. The structural features of PcFK1 represent an
interesting protein scaffold for future protein engineering.
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Introduction
Despite recent scaling up of control efforts, malaria remains a
major public health problem [1]. The development of novel
control tools is urgently needed as Plasmodium falciparum has
become resistant to multiple drugs [2] while vector mosquitoes
resist to insecticides in many areas. The development of novel
antimalarials is a priority [3]. Recently, parasite proteases involved
in egress and/or invasion of the host erythrocytes have emerged as
potential drug targets. In particular, the subtilisin-like serine
protease PfSUB1 is involved in the maturation of parasite proteins
implicated in the egress of the P.falciparum merozoite from the
infected erythrocyte [4] and in the maturation of the major
merozoite surface protein (MSP1) required for successful erythro-
cyte invasion [5].
In addition to therapies based on small molecules such as
chloroquine, artemisinins, quinine and atovaquone [6], the
development of new classes of molecules based on proteins or
peptidomimetics [7] [8] is an active field of research. Among
antiplasmodial bioactive proteins, dermaseptin S4 (DS4) is able to
inhibit irreversibly the growth of the parasite, through a cytotoxic
hemolytic activity [9]. Dermaseptin S3, a related protein, acts in
an analogous manner to DS4 by inhibiting P. falciparum growth in
vitro, but without hemolytic activity [10]. Choi et al. have isolated
from the venom of the tarantula Psalmopoeus cambridgei two novel
peptides that inhibit the intra-erythrocytic cycle of P. falciparum
[11]. Psalmopeotoxin I (PcFK1) is composed of 33 residues, while
Psalmopeotoxin II (PcFK2) has 28 residues; both have three
disulfide bridges and belong to the cystine knot motif superfamily.
These two peptides inhibit the growth of the parasite with an IC50
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21812in the low micromolar range, show no antifungal or antibacterial
activity and are neither hemolytic nor do they affect the growth or
viability of human epithelial cells. The authors concluded that
PcFK1 and PcFK2 interact specifically with P. falciparum
parasitized erythrocytes. Later on, the NMR structure of PcFK1
revealed that it belongs to the ICK structural superfamily with
structural determinants common to several neurotoxins that act as
ion channel effectors. Based on this structural similarity it was
proposed that the molecular target for PcFK1 could be an ion
channel [12], but no experimental data was provided to support
this hypothesis. Using bioinformatics analysis, protein-protein
docking methods and free energy calculations we formulate here
the hypothesis that PfSUB1 is a target for this small protein. We
confirm this hypothesis by experimental testing on PfSUB1 specific
enzymatic assay using a PfSUB1 purified and active recombinant
enzyme. The understanding of how PcFK1 may interact with
PfSUB1 provides important information for using this small
protein as a scaffold in order to improve its inhibitory activity
using computational protein design [13].
Results
Sequence Comparison
The sequence of the observed or predicted PfSUB1 cleavage site
in its various protein substrates is listed in Figure 1. Like other
subtilisin-like proteases, PfSUB1 recognizes a broad range of
sequences, but shows a pattern of preferred amino acids with
hydrophobic aliphatic side chains in P4 while polar or positively
charged residues are often present in P3. Small amino acids (gly,
ala) are preferred in P2 while for all other positions (P1, P1
0
,P 2
0
,
P3
0
), the enzyme prefers polar and negatively charged side-chains.
As shown in Figure 1, two regions from PcFK1, called here
Site1 and Site 2, show a profile comparable to the PfSUB1
substrate sequences. Both display residues present in the natural
substrate sequence(s). For Site 1, the greatest similarity is localized
at P1 and P1
0
, with the aspartate and asparagine residues,
respectively, being identical to the autocatalytic sequence of
PfSUB1. The P4 presents an isoleucine that is fairly similar to
valine, the most represented residue in P4. Site 2 shares even more
similarities than Site 1. Position P4, P2 and P1 are occupied by a
valine, an alanine and a glutamine respectively, the most
represented residues among all substrate sequences. These
observations led us to formulate the hypothesis that PfSUB1
could be a target for the PcFK1 parasite inhibitor.
Structural Analysis
The sequence similarities indicate two possible sites that could
interact with PfSUB1. As Figure 2 shows, these sequences are on
the surface and accessible for a potential interaction with a protein
partner. An analysis of the solvent accessible surface with DSSP on
the 25 NMR conformers (Figure 3.A) showed that both sites are
quite solvent accessible, but that Site 2 shows a higher solvent
accessibility of position P1 (Q15) compared to the P1 of site 1 (D7).
Position P1 in protein inhibitors has a central role in the
interaction with serine-proteases [14]. In PfSUB1, the importance
of the P1 was investigated using recombinant PfSUB1 with a
mutation in the P1 position of the autocatalytic cleavage sequence.
A substitution with a leucine in this crucial position resulted in a
partially maturation-defective enzyme that was converted to active
protease with much reduced efficiency, suggesting a central role
for the P1 residue of the autocatalytic cleavage sequence [15]. We
also analyzed the fluctuation from the average structure of each
residue, finding that Site 2 is more flexible, in particular position
Q15 (Figure 3.B), the potential P1 position. A relatively flexible P1
will allow its side-chain to adapt to the S1 pocket more efficiently.
Overall, these observations suggest that Site 2 could be more likely
responsible for an interaction with PfSUB1.
PfSUB1 Modeling
The validation of a model is a critical step in comparative
homology modeling. After creating a pool of models using the
homology modeling suite Modeller (see Material and Methods),
we selected models with the most precise catalytic site geometry
and an overall good structure quality. Correct distances among
key atoms in the catalytic site are necessary for the function of the
enzyme and can be used as indicator of a reliable model. We
analyzed the geometry for all templates we used in our homology
modeling protocol and we defined a range for each distance. A
model is accepted for further analysis only if all its distances fall
within the range that we defined (within lower and upper range,
see Table 1).
We ranked the filtered models according to quality using several
structure analysis programs included in the online server SAVS
(see Material and Methods), selecting the best 10 for further
analysis. Of the 10 models we selected the one that ranked best of
DOPE (Discrete Optimized Protein Energy) Z-score [16] (20.97)
and Prosa Z-score (25.98). In Table 2 we show the comparison of
the DOPE score and DOPE Z-score of our best model to the
templates used in the modeling procedure. The negative value
close to 21.0 suggest that the model is of good quality and likely to
be native-like. We also plotted the DOPE energy by-reside as
shown in Figure 4. Despite a region around residue number 60
with high energy, all residues forming the binding regions have a
good DOPE energy if compared to the templates. To further
evaluate the quality of our modeling procedure, we compared the
models among each other and also with models obtained by
several homology modeling servers. In Figure 5 we plotted the
RMSD from the average structure of our 10 best models on a
Figure 1. Alignment of PcFK1 with substrate sequences of
PfSUB1. The sequence alignment of PcFK1 (pdb: 1X5V) with the
sequences recognized by PfSUB1 shows a comparable residue profile for
Site 1 and Site 2. In particular, Site 2 shows the highest sequence similarity
with the most conserved residues among the substrate sequences. The
shades of blue indicate the degree of conservation among the sequences.
The SERA4 and SERA6 processing sites are predicted from sequence
alignments and homology with the experimentally determined SERA5
processing sites [4]. All other sites shown here were experimentally
determined by amino-acid sequence analysis [5].
doi:10.1371/journal.pone.0021812.g001
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loops or regions incorrectly modeled because of missing structural
information in the templates. Considering the overall rigidity of
subtilisins and of serine proteases [17], the regions with high
flexibility are probably not correctly modeled. The results showed
that the residues that constitute the binding region are structurally
conserved and that regions with high RMSD are not close to the
binding region. By comparing our best model with models
obtained by several homology modeling servers (Figure 5.B) we
observed that for the residues forming the binding interface our
models have the lowest RMSD. This increases the confidence that
these positions are probably correctly modeled.
Table 3 shows the overall RMSD of each server model to our
PfSUB1 model and their coverage. Models obtained from Phyre
and ESyPred3D servers are the most similar to ours with RMSD
of 3.78 A ˚ and 3.66 A ˚, respectively. The analysis of the trajectories
with molecular dynamics simulations revealed that the model is
stable and behaves similarly to two subtilisins used as templates
(data not shown).
Docking to PfSUB1
We employed an ensemble–docking strategy, using 25 NMR
conformers of PcFK1, and used the distance between the
carbonyl-carbon of P1 and the hydroxyl group of the catalytic
serine (S268) as a criterion for a well-docked model. Analyzing
some X-ray structures of complexes of subtilisins with their protein
inhibitors we observed an average distance of 2.72 A ˚. The docking
results shown in Figure 6 indicate that Site 2 has a distance that is
closer to 2.72 A ˚ when compared to Site 1, confirming that Site 2 is
more likely the region responsible for the inhibition of PfSUB1.
Nonetheless, all docking solutions show a larger distance than
what is observed in the X-ray structures of complexes. This can be
explained by the imperfections in the model and a docking
protocol that does not include enough flexibility, in particular at
the level of the receptor (PfSUB1).
Refinement of docked structures
We therefore took the best 10 solutions based on the distance
criterion and refined them using a restrained molecular dynamics
protocol where we restrained the distance between the hydroxyl
group of the catalytic serine and the carbonyl-carbon of Gln in P1.
In a related study, we applied restrained molecular dynamics in
order to refine docking poses obtained from an ensemble-docking
protocol, showing the importance of this refinement in order to
obtain high-accuracy docking models (Bastianelli et al., submitted).
In Table 4 we compared the MDs of the ten solutions with and
Figure 2. Structure sites localization. Two views of the structure of PcFK1 (pdb: 15XV). (top) Site 1 is highlighted in red sticks while Site 2 in blue
sticks and residues in position P1 are shown in darker blue or red. (bottom) Both sites are at the protein surface and therefore accessible to protein-
protein interaction.
doi:10.1371/journal.pone.0021812.g002
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.5 A ˚ suggesting that the refinement procedure do not introduce
distortion in the structure. In addition, we evaluated if the
refinement procedure could modify the structure of the spider
toxin by comparing the NMR ensemble with the structures after
refinement. In the NMR ensemble, the average RMSD from the
average structure is 1.62 A ˚ . We ran MDs (on the 5 most
representatives structures determined by clustering) and we found
an average deviation from the initial structure in the first 1.720 ns
of 1.32 A ˚ . We then calculated the RMSD for the spider toxin
structure during the ten refinements and compared to the initial
structure of the complex. In all ten cases the deviation was less
than 2 A ˚ suggesting that the structures are also not distorted. After
the refinement, the structures of the complex show a reduction of
RMSD to their average structure indicating that the refinement
procedure allows different docking poses to converge to a more
similar docked conformation (Figure 7). We also calculated the
free energy of binding on the 10 complexes we refined. Free
Figure 3. Solvent exposure and RMSF for PcFK1. The two sites are highlighted in red for Site 1 and blue for Site 2 where D7 and Q15 are the P1
position of Site 1 and Site 2, respectively. (A) shows that most of residues are solvent accessible apart from the cysteine side-chains forming
disulphide bridges. The glutamine in position 15 is significantly more exposed than the aspartate in position 7. The RMSF analysis (B) shows that
PcFK1 has a fairly rigid structure with few exceptions at the N and C-terminal, and the tyrosines and arginines. The P1 residue of Site 2 (Q15)
fluctuates more than its counterpart of Site 1 (D7).
doi:10.1371/journal.pone.0021812.g003
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been used in the past to estimate successfully absolute free energy
of bindings [18] [19] [20] [21]. The average free energy of binding
calculated from the MDs of the 10 complexes was
25.01+6.27 kcal/mol, which corresponds to an inhibition in
the low to medium micromolar range.
Enzymatic and Culture Tests
We then tested the capacity of PcFK1 to inhibit the PfSUB1
enzyme activity in an enzymatic assay using the recombinant
PfSUB1 enzyme and a peptidic substrate derived from MSP1.
PcFK1 indeed inhibited the enzyme with a constant of inhibition
(Ki) of 29.3 mM+10.6 (SEM), confirming an inhibitory activity of
PcFK1 in the medium micromolar range. If we translate this Ki
value into free energy of binding we obtain 26.37 Kcal/mol, a
value that deviates by less than 2 kcal/mol from our predictions of
25.01+6.27 kcal/mol. To further document PcFK1-mediated
inhibitory capacity, we also tested PcFK1 against the recombinant
Plasmodium vivax SUB1 (PvSUB1). PfSUB1 and PvSUB1 share
more than 68% sequence identity of their catalytic regions, most of
sequence differences being located outside the binding pocket
(Figure 8). Due to this high degree of sequence similarity they
cleave substrates with comparable sequences. PcFK1 inhibits
PvSUB1 with a Ki of 36.3 mM+6.9 (SEM). We determined the
EC50 of PcFK1 on the asynchronous culture of P. falciparum intra-
erythrocytic cycle and found a high micromolar inhibition of
116 mM+6 (SEM). PfSUB1 is involved in both the merozoite
egress from red-blood cells (RBC) and their subsequent invasion
into fresh RBC. The results on Figure 9 show that PcFK1 indeed
inhibits the egress-invasion steps of P. falciparum merozoites
(Figure 9.D). The experiments performed on the PfSUB1 and
PvSUB1 active recombinant enzyme and on the P. falciparum
culture in vitro further confirm our initial hypothesis that PcFK1
indeed targets the parasite SUB1 enzyme activity.
Modeling the interaction
Being able to identify the mode of interaction of PcFK1 is
crucial when envisioning a protein engineering approach to
improve PcFK1 biological activity. The first step is the
identification of the residues that are important for the interaction
of PcFK1 with PfSUB1. The neighbor search in Figure 10 shows
the number of average residues of PfSUB1 that are in contact with
each of PcFK1 residue in all 10 MD trajectories. Residues in P2
and P1 show the highest number of contacts with PfSUB1
residues, of 10.3 and 12.2, respectively. Overall, Site 2 makes more
residue contacts than other regions of PcFK1. A more informative
by-residue decomposition of the relative free energy (not
decomposing the entropy) shows that the P1 residue contributes
for 25.65 Kcal/mol, accounting for 25% and P2 for a 17% of the
total free energy of binding (Figure 10). More than 75% of the free
energy of binding from PcFK1 comes from Site 2 residues (P4, P3,
P2, P1, P1
0
). Position P1 and P2 seem to be the most important
residues for the interaction with PfSUB1, and they are the most
interesting residues for being engineered.
Discussion
PcFK1 was previously shown to inhibit the growth of P.
falciparum at the erythrocytic stage but no molecular target was
assigned. Based on a series of observations that included sequence
analysis, docking to the model of the enzyme and free energy
calculations, we hypothesized in this paper that PcFK1 could act
as an inhibitor of PfSUB1. The enzymatic assays not only showed
that indeed PcFK1 inhibits the recombinant purified active
PfSUB1 enzyme, but also with an affinity (Ki) in very good
agreement with our bioinformatics calculations. PcFK1 inhibits
not only PfSUB1 but also PvSUB1, its orthologous protein in
Plasmodium vivax, the main causative agent of malaria outside the
african continent. This was an important additional confirmation
of our findings on PfSUB1 since the two enzymes are likely to have
the same biological function and display very close structures of
the binding region (Figure 8). The inhibition of both P. vivax and P.
falciparum by PcFK1 indicates that the interaction is mediated by a
sequence in PcFK1 that is similar to the substrate sequences
recognized by SUB1. Our computational analysis showed that Site
2 is most likely the sequence responsible of this inhibition. The
tests performed on the in vitro culture of P. falciparum intra-
erythrocytic cycle further confirmed the enzymatic results
indicating that the anti-Plasmodium activity of PcFK1 is mostly
directed towards the daughter parasite egress from and subsequent
invasion into the human erythrocytes, the biological stages where
PfSUB1 is known to play a crucial role. It is noteworthy that the
pro-peptide of PfSUB1 is also a strong inhibitor of the enzyme [22]
but due to its large size (*30 kDa) and since its anti-parasitic
effect on the P. falciparum in vitro culture has not been established, it
is not an interesting scaffold for engineering a potent anti-parasite
Table 1. Subtilisin catalytic site geometries.
Distance lower-range upper-range
HIS@CA-SER@CA 8.3 8.72
HIS@CB-SER@CB 6.44 6.89
HIS@CA-ASP@CA 7.22 7.46
HIS@CB-ASP@CB 5.83 6.61
SER@CA-ASP@CA 9.87 10.11
SER@CB-ASP@CB 8.15 8.53
SER@OG-HIS@NE2 2.57 3.36
ASP@CG-HIS@ND1 3.15 3.35
ASN@CG-SER@CB 6.34 6.74
SER@OH-surface 1.58 1.60
The distances were obtained by analyzing the geometry of the catalytic site
(Asp-His-Ser) of the templates used in the modelling of PfSUB1. The Asn is the
residue forming the oxyanion hole.
doi:10.1371/journal.pone.0021812.t001
Table 2. Comparison of PfSUB1 model to templates.
Structure DOPE score DOPE Z-score
PfSUB1 235609.20 20.97
1BH6 231888.00 22.197
1DBI 232528.70 22.168
1GCI 230067.13 22.266
1R0R 231499.16 22.062
1SCJ 231205.20 22.046
1THM 231950.16 22.269
1TO2 231323.86 21.914
The model of PfSUB1 shows a negative DOPE Z-score, usually an indication of a
model of good quality. Scores lower or around 21.0 are likely to be native-like.
The other templates show lower Z-score because they are experimental X-ray
structures.
doi:10.1371/journal.pone.0021812.t002
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to the family of proteins with a cysteine knot motif. Proteins with
this unique structural scaffold can be extraordinarily stable and
have a broad range of bioactivities. This can be exploited for
developing more active peptides, via molecular engineering
approaches [23].
The docking analysis and the MD based refinement proposed a
model of interaction where residues in P1 (glutamine) and P2
(alanine) establish most contacts with PfSUB1. The understanding
of the structure-function relationship for PcFK1 allows to gain
more insights on the structure of SUB1 and to guide the rational
engineering of PcFK1 in order to improve its inhibitory activity.
Most of protein engineering studies [24] use some of the methods
we described in this study with the objective of engineering a
protein scaffold for a specific biological activity, such as binding to
another protein target [25]. In this paper we used these methods in
a predictive fashion, in a computational reverse engineering
process. Our results show that such a strategy could indeed be
powerful to assign a molecular target to peptidic compounds,
which are known to display a biological effect, but remain orphan
of biological target. Approaches similar to the one we described in
this study will have an increasing importance as our understanding
of protein-protein and protein-ligand interactions advances.
Molecular modeling methods for docking proteins [26] and
calculate free energy [27] have been used with some successful
results in computational protein engineering studies and advance-
ments in algorithms and computational power will provide a
greater help in the future to guide protein engineering. We can
envision using similar methods to the ones we used in this paper to
engineer PcFK1 in order to improve its inhibitory activity against
PfSUB1. This could lead to new protein-based therapeutic
approaches targeting novel mechanisms of action.
Materials and Methods
Bioinformatics analysis
Protein modeling. To obtain a homology model of PfSUB1
we retrieved sequences from the Uniprot database [28] (www.
uniprot.org) and structure files of the templates from the PDB [29]
(www.rcsb.org). The following templates were used: 1TO2,
1THM, 1SCJ, 1R0R, 1GCI, 1DBI, 1BH6. Template structures
were cleaned of any heteroatom or water molecule and sequences
were submitted to the Expresso server [30] (3D-TCOFFEE) using
default parameters. 200 models were generated with Modeller
v9.1 [16] using slow molecular dynamic refinement and repeated
optimization.
Profit (http://www.bioinf.org.uk/software/profitt/index.html)
was used to run structure alignment and calculate RMSD using
the ITERATE option. Considering the high sequence identity
(.68%) shared between PvSUB1 and PfSUB1 active site domains,
we modelled PvSUB1 starting from our model of PfSUB1. Binding
pocket residues were defined according to the interaction of
canonical inhibitors with subtilisins. PfSUB1: 152–162, 127–134,
266–269, 179–182, 90 (His), 34 (Asp), 268 (Ser); PvSUB1:
PvSUB1: 152–162, 127–134, 265–268, 179–182, 90 (His), 34
(Asp), 267 (Ser). Structure quality was assessed with several
softwares such as Procheck [31], WhatCheck [32] [33], Errat [34]
and Verify3D [35] [36] using SAVS server (nihserver.mbi.u-
cla.edu/SAVS1/). Prosa calculations were obtained using ProSA-
web [37].
The NMR structure of PcFK1 (PDB: 1X5V) was retrieved from the
PDB [29]. The RMSF was calculated with AMBER [38] using the
average structure from the 25 NMR conformations. Relative solvent
exposure was obtained using Biopython and DSSP [39]. Images of
protein structure were rendered with the software Pymol [40].
Figure 4. DOPE profile comparison with templates. The graph shows the DOPE by-residue profile of our best model of PfSUB1 against three
templates used in the modeling where in gray are shown the residues forming the binding region. Despite a region with a high energy (around
residue 60) all regions forming the binding region show a relatively good DOPE energy. Missing values in the templates are due to gaps in the
sequence alignment.
doi:10.1371/journal.pone.0021812.g004
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was docked against the model of PfSUB1 using the ZDOCK
software [41]. The docking search was limited to the binding
region of PfSUB1 defined by the following residues:D34, H90,
L123, K127, L128, G129, G151, S152, F153, S154, F155, D156,
S179, A180, S181, N182, C183, K203, G266, T267, S268, M269.
We performed the docking search using full rotational sampling
and generated 2000 solutions per NMR conformer, for a total of
Figure 5. RMSD among models of PfSUB1. In A the RMS fluctuation on a per-residue basis is plotted for the 10 best models. Gray rectangles
highlight the residues forming the binding region. (B) Comparison of our best model with models obtained from several modelling servers. Profit was
used to calculate by-residue RMSD where the structure alignment was performed using Needleman and Wunsch sequence alignment.
doi:10.1371/journal.pone.0021812.g005
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to the distance between the P1 carbon-carbonyl and the hydroxyl
of the catalytic serine of PfSUB1 (S268).
Docking refinement. We refined the complexes using a
protocol of restrained molecular dynamics where the distance
between the hydroxyl of the reactive serine of PfSUB1 was
restrained between 3 to 5 Angstroms to the peptidic carbon in P1.
We previously validated this procedure in a complex between a
subtilisin and a protein inhibitor showing an improvement of the
quality of the docking (Bastianelli et al. 2010, submitted). The
refinement stage consisted of three phases, each one consisting of
120.000 steps. In the first phase, the receptor (PfSUB1) was kept
‘‘rigid’’ by applying a Cartesian restraint with a force-constant of
10 kcal/mol/A ˚ 2, and the distance restraints were switched on/off
every 15.000 steps. In the second phase a Cartesian restraint with
a force-constant of 10 kcal/mol/A ˚ 2 was applied only to heavy
main-chain atoms with fully flexible side-chains, and in the third
phase the force-constant of this Cartesian restraint was reduced to
0.01 kcal/mol/angstrom2. During these phases, the ligand
(PcFK1) was kept completely flexible. An additional 1.0 ns of
regular MD simulations was performed to allow the system to
relax into its final configuration.
Molecular dynamic simulations. All molecular dynamics
simulations (MDs) were performed using the SANDER code from
the AMBER 9 [38] simulation suite and the ff99SB force-field
[42]. Starting structures were first minimized in vacuum, and the
system was then hydrated using TIP3P [43] water molecules and
neutralized by adding an appropriate number of monovalent
counterions. To remove bad contacts between solute and solvent
molecules, we performed a two stage minimization protocol, using
a Cartesian restraint on the solute with a force-constant of
10 kcal/mol/A ˚ 2 in stage 1, and 1 kcal/mol/A ˚ 2 in the second for a
total of 500 steps. During the equilibration/heating and
production dynamics all covalent bonds to hydrogens were
constrained with the SHAKE [44] algorithm. All simulations
were performed under periodic boundary conditions with a time
step of 2 femtoseconds. Electrostatic interactions were treated
using the PME [45] (Particle Mesh Ewald) method with a direct-
space sum cut-off of 8 A ˚. Rapid initial thermal equilibration to
3000K was performed over 20 ps under constant-volume
conditions followed by 10 ps equilibration at constant-pressure.
The production run MD simulations were performed using using a
weak-coupling thermostat with a time constant of 2.0 ps and a
pressure relaxation time of 2.0 ps. Post MDs processing and
analysis was performed with the ptraj utility of AMBER 9.
Free energy calculations. For our calculations and analysis
we used 50 snapshots (every 20 ps) out of 1 ns MD simulation for
each solution. Residues at the interface were selected with the
neighbor search implemented in Biopython and a distance cutoff
of 5 A ˚ between the center of mass of two aminoacids. The tool
MM-PBSA [18] in AMBER was used to calculate the free energy
decomposition. We used the GBSA model proposed by Tsui and
Case [46] with an external dielectric of 80 and internal dielectric
of 1.0. For calculating the nonpolar contribution, the surface
tension coefficient (SURFTEN) was set to 0.0072 and the surface
Figure 6. Docking Results. The plot illustrates the 2000 solutions
with the highest Z-Score obtained from the ensemble docking
performed employing the 25 NMR conformers of PcFK1 against the
model of PfSUB1. The results show that Site 2 has a distance of the
carbon-carbonyl to the hydroxyl of the catalytic serine close to the
average value observed in many other complexes (*2.7 A ˚). This
suggests that Site 2 can be the region responsible for the interaction
with PfSUB1.
doi:10.1371/journal.pone.0021812.g006
Table 3. RMSD to server models.
Web-server RMSD Interface RMSD Coverage %
3D-JIGSAW [53] 6.63 A ˚ 2.14 A ˚ 100%
Consensus Server [54] 5.41 A ˚ 2.03 A ˚ 82%
CPH [55] 5.4 A ˚ 1.89 A ˚ 78%
ESyPred3D [56] 3.66 A ˚ 1.65 A ˚ 85%
SWISS-MODEL [57] 5.24 A ˚ 2.78 A ˚ 78%
Phyre [58] 3.78 A ˚ 1.49 A ˚ 85%
PfSUB1 models were built using several available homology modeling servers.
The models obtained with ESyPred3D and Phyre servers are the structurally
closest to our model of PfSUB1 with respectively a RMSD of 3.66 A ˚ and 3.78 A ˚.
The interface RMSD were calculated on the residues (see Materials and
Methods) that defines the binding pocket. The coverage refers to the
percentage of our model structure that was covered by other servers.
doi:10.1371/journal.pone.0021812.t003
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(SASA) was calculated using the ICOSA method. The entropy was
estimated using the nmode tool in AMBER using a distance-
dependent dielectric constant of 4 and a DRMS (convergence
criterion for the energy gradient) of 0.0001.
PcFK1 synthesis, folding and purification
PcFK1 was chemically synthesized with an extra serine at the C-
term. We made this choice to have a sequence closely similar to
the NMR structure of PcFK1,which carries a homoserine lactone.
As there is no difference in activity [12] between the wild-type
PcFK1 with an amide at the C-term and the one carrying the
homoserine lactone, it is likely that the C-term does not play a role
in the activity. To be sure of this we also tested the wild-type
PcFK1 with PfSUB1, with no major changes in the activity if
compared to the one carrying an extra serine at the C-term. Fully
reduced PcFK1 (desalted, 35%–60% pure as assessed by HPLC)
was obtained from GenScript Corporation, Piscatway, NJ, USA.
We dissolved the peptide (50 mg) in 75 mL of KH2PO4 buffer
(0.2 M, pH 8.2), allowing air-oxidation at room temperature
under gentle stirring. Disulphide bridges formation was monitored
with Ellman’s test [47] and analytical HPLC (column ACE C18,
5 microns, 12564.6 mm, eluent A: 0.1% TFA/H2O, eluent B:
60% CH3CN=H2O/0.1% TFA) using a 30 min linear gradient of
25% to 55% B at 1 mL flow rate (monitoring at 210 nm). When
Ellman
0
s tests were negative and HPLC monitoring showed no
traces of starting materials (after 3 to 5 days), the reaction mixture
was centrifuged and the supernatant loaded onto a preparative
HPLC column (Merck Lichrospher C18, 10 microns,
250625 mm). The peptide was eluted with a 90 min linear
gradient of 25% to 55% B at 10 mL flow rate (monitoring at
220 nm). The fractions containing the oxidized peptide were
combined and lyophilized to yield 15 to 30% of the desired
peptide. Successful oxidation was confirmed by mass spectrometry
(MALDI-Tof, Bruker Biflex III). All the experiments were
performed using three different synthesis lots of PcFK1 and they
Figure 7. RMSD Map. The plot shows the distribution of the RMSD for the best 10 docked solutions before and after refinement where the average
structure was set at (0,0). The map was obtained by calculating the RMSD distance matrix among all solutions and their averages before and after the
refinement. The RMSD distance matrix was then represented in a 2 dimension plot. While starting docked solutions are dispersed with RMSD values
even .6A ˚, after the refinement the RMSD is ,3A ˚, indicating a convergence to a more similar docked conformation.
doi:10.1371/journal.pone.0021812.g007
Table 4. Comparison of RMSD along MDs in refined and non-
refined docked complexes.
Solution RMSD NO-REF RMSD REF
1 2.62 2.38
2 2.67 2.41
3 2.69 2.36
4 3.01 2.89
5 2.99 2.76
6 2.65 2.33
7 2.77 2.40
8 2.62 2.32
9 2.98 2.53
10 2.78 2.43
The RMSD from the first snapshot of the MDs were calculated for the 10 docked
solutions with and without refinement. In all cases the difference in terms of
RMSD is less than .5 A ˚ meaning that the refinement procedure does not
introduce distortions in the structures. For both refined and non-refined MDs
we calculated the RMSD over the 1 ns unrestrained MDs. NO-REF: solutions not
refined. REF: solutions refined.
doi:10.1371/journal.pone.0021812.t004
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between PfSUB1 and PvSUB1 (in red). The residues constituting the catalytic triad (Asp,His,Ser) are represented in green in A and as green sticks in B.
In Figure B we highlight lysine 203 (red sticks) that is replaced by an arginine in PvSUB1. This is the only sequence difference that we can find in the
vicinity of the binding pocket.
doi:10.1371/journal.pone.0021812.g008
Figure 9. Analysis of merozoites egress/invasion steps on P. falciparum in vitro culture. In vitro synchronized culture of P. falciparum
composed of 0.5% of segmented schizonts was incubated for 12 hr in serum-containing medium and schizonts transition to newly formed
trophozoites was analyzed by flow cytometry. Gates were converted to two-dimensional plots illustrating the expected merozoites egress defect in
presence of 10 mM E64 [51], but also in presence of 200 mM of PcFK1. 91.6% and 56.2% of inhibition of newly formed trophozoites and equivalent
segmented schizont accumulation were observed with 10 mM E64 and 200 mM PcFK1 respectively, when compared to the mock control. Mock
condition corresponds to a classical P. falciparum culture in presence of 2% DMSO, the vehicle of PcFK1.
doi:10.1371/journal.pone.0021812.g009
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ity was confirmed by NMR spectra analysis.
PfSUB1 and PvSUB1
Production. Recombinant baculoviruses expressing recombinant
forms of PvSUB1 and PfSUB1 (described in Bouillon et Giganti et al.,
in preparation) were amplified by infecting 56106 Sf9 cells in T-25
culture cultivated in Insect XPRESS medium (Lonza) supplemented
with 5% fetal calf serum and 50 mg/L gentamycin. The final viral
stock was titrated by end-point dilution assay. For large-scale protein
production, Sf9 cells (1 L at 36106 cells/mL) were infected for 72 h
with recombinant baculovirus at a MOI of 10 in Insect XPRESS
medium supplemented with 50 mg/L gentamycin and 0,5 mg/mL of
tunicamycine.
Figure 10. Interacting residues. (A) Number of residues of PfSUB1 interacting with each residue of PcFK1 on average from the 10 MDs of the best
solutions. Most of contacts are made by residues in P2 (A14) and P1 (Q15). (B) Free energy decomposition on a per-residue basis with separate
contribution of side-chain and backbone.
doi:10.1371/journal.pone.0021812.g010
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and active PvSUB1 or PfSUB1 recombinant enzymes was
harvested, centrifuged 30 min at 2150 rcf to remove cells and
cellular debris and concentrated/diafiltrated against D-PBS 0,5 M
NaCl; 5 mM Imidazole (loading buffer). The protein was purified
on an AKTA purifier system (GE Healthcare). The sample was
loaded onto a 3 mL TALON Metal affinity resin (Clontech
Laboratories) previously equilibrated in loading buffer, thus
allowing the binding of PvSUB1 or PfSUB1 recombinant
proteins via the addition of a 66-histidines tag in its C-terminal.
The column was extensively washed with loading buffer and the
bound protein was eluted with a linear gradient from 5 to 200 mM
imidazole in D-PBS 0,5 M NaCl. Fractions containing PvSUB1 or
PfSUB1 were pooled concentrated using a Amicon Ultra 15
(10000 MWCO) and size fractionated onto a HiLoad 16/60
Superdex 75 column equilibrated with 20 mM Tris pH 7,5,
100 mM NaCl to remove imidazole and exchange buffer.
Throughout the purification procedure, fractions were
monitored by absorbance (280 nm) and analyzed by Coomassie
blue staining of SDS-PAGE gels and activity assay. Fractions
containing the PvSUB1 or PfSUB1 purified proteins were pooled
and protein concentration was determined using the BCA Protein
Assay following manufacturers recommendations (Bio Basic).
Purified PvSUB1 or PfSUB1 recombinant proteins were stored
at 2200C following the addition of 30% v/v of pure Glycerol.
Enzymatic Test
Forthekinetic assaysweused the recombinant PvSUB1/PfSUB1
enzymes and specific peptide substrates whose sequence are
deduced from the auto-maturation site of each one: KLVGADDV-
SLA, with cleavage occurs between the two aspartates for PvSUB1
and KLVSADNIDIS with is cleaved between the aspartate and the
asparagine for PfSUB1. The substrates used had the fluorophores/
quencher Dabsyl/Edans at each edge. The enzymatic assay were
performed with 13 ng of purified PvSUB1 or PfSUB1 in 20 mM
Tris pH 7.5 and 25 mM CaCl2 at 370C. The apparent Km of
PfSUB1 and PvSUB1 for their substrate being 30,2 mM+3,4 and
19,7mM+1,7 respectively (described in Bouillon et Giganti et al, in
preparation), all further experiments were performed using 25 mM
of substrates. For the determination of the Ki, the compounds,
previously resuspended in ultra-pure distilled water at 10 mM, were
tested at ten different concentrations ranging from 1 mM to 2 mM
following sequential 1:2 dilutions. The final mixture was distributed
in duplicate into a 384-well black microtiter plate (Thermo
Scientific) and the fluorescence was monitored every 3 minutes
for 90 min at 370C in a Labsystems Fluoroskan Ascent spectro
fluorometer using the excitation and emission wavelengths of 460/
500 nm. The slope of the linear part of the kinetic was determined
in an Excel (Microsoft) spreadsheet. Every steps of the enzymatic
assay were done on ice to make sure that the protein was not active
before the measure of the fluorescence. The Ki and IC50 values
were determined (N=3) using GraphPad Prism software.
Culture Tests
Asexual cultures of reference clone 3D7 obtained from MR4
(www.MR4.org) was maintained in continuous cultures following
the method of Trager an Jensen [48], except that the medium was
composed of RPMI 1640 medium supplemented with 10%
decomplemented human serum (AB+), hypoxanthine 100 mM,
gentamycin 50 ng/mL. Parasites were incubated at 370Ci na n
atmosphere composed of 5%O2, 5%CO2 and 90%N2. Quanti-
tative assessment of the antimalarial activity of PcFK1 was
performed as described by Desjardins et al. [49] and Bougdour
et al. [50] on asynchronous culture of clone 3D7 (0,5% parasitemia
and 1% hematocrit), except that the parasites were in contact with
the drug for 48 hours, the culture medium contained 10 mM
hypoxanthine. EC50 have been determined following nonlinear
regression analysis using HN-NonLin V1.1 software (http://
malaria.farch.net).
A synchronised culture composed of segmented schizontes of P.
falciparum (3D7 clone) at 0.5% parasitemia and 1% hematocrit is
performed in a 24 wells plate. An aliquot corresponding to 10% of the
starting culture (T0) is diluted in a solution at 0.04% of glutaraldehyde
in PBS (Dulbecco) and store at 40C for further flow cytometry analysis.
E64 (trans-Epoxysuccinyl-L-leucylamido(4-guanidino)butane, Sigma-
Aldrich), a cysteine-protease inhibitor known to block the egress of P.
falciparum merozoites in vitro [ 5 1 ]w a su s e da sap o s i t i v ec o n t r o la taf i n a l
concentration of 10 mM, while PcFK1 was tested at a final
concentration of 200 mM and a mock control (T12)r e c e i v e ds t e r i l e
water, in which PcFK1 was resuspended. The final experiment ended
after an incubation of 12 hours, allowing the rupture of the parasitized
erythrocytes, the egress of merozoites and their subsequent entry into
fresh red blood cells. 10% of the cultures are resuspended in a solution
of 0.04% glutaraldehyde in PBS (Dulbecco) and store at 40C for flow
cytometry analysis. The progress of the parasitaemia from segmented
schizont to newly formed trophozoites was assessed by flow cytometry
after staining samples by the DNA-binding fluorescent dye, YOYO-1,
as previously described by Li and colleagues [52] with some
modifications. Briefly, following a centrifugation at 450 g for 5 min
the pelleted cells were re-suspended in 0.3 ml PBS (Dulbecco)
supplemented with 0.25% Triton X-100 and incubated for 10 min
at room temperature. After centrifugation, the permeabilized cells were
re-suspended in 500 mLo fR N a s ea t5 0mg/mL and incubated for at
least 3 h at 370C. Then YOYO-1 solution (Invitrogen) was added to
obtain a final concentration of 500 ng/mL. Samples were incubated at
40C in darkness for at least 4 h and centrifuged at 450 g for 5 min. The
pelleted cells were re-suspended in 0.3 ml PBS before being analysed
by flow cytometry using a FACSCanto(BD) apparatus and the data
were analyzed using FlowJo (Tree Star) software. The fluorescent signal
of YOYO-1 dying cells was collected in FL-1 channel after
compensation of fluorescent intensity in the FL-2 channel.
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